$LUCD News

BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing

Lucid Diagnostics Receiving Medicare Payments For Its EsoGuard Esophageal DNA Test; Closed $15M Private Placement Of Its Newly Designated Series C Convertible Prefs To Existing Long-Term Shareholders On October 21

Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways

Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.5

Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript

Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says

BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth

Lucid Diagnostics Inc. Q2 2026 Earnings Call Summary

Lucid Diagnostics Inc (LUCD) (Q2 2026) Earnings Call Highlights: Strategic Pivot to High-Value ...

Lucid Diagnostics Inc. 2026 Q2 - Results - Earnings Call Presentation

Lucid Diagnostics Q2 Earnings Call Highlights

Lucid Diagnostics Inc. (LUCD) Q2 2026 Earnings Call Transcript

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

Lucid Diagnostics Q2 2026 Earnings Call: Complete Transcript

Lucid Diagnostics Q2 Adj. EPS $(0.08) Misses $(0.07) Estimate, Sales $1.474M Miss $1.943M Estimate

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

Lucid Diagnostics to Participate in Upcoming Investor Conferences

Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026